Poniard Pharmaceuticals (PARD) Price & Analysis

7 Followers

PARD Stock Chart & Stats

$0.31

>-$0.01(-99.00%)

At close: Dec 27 4:00 PM EST

$0.31

>-$0.01(-99.00%)

Day’s Range― - ―

52-Week Range$0.31 - $0.31

Previous CloseN/A

Volume125.00

Average Volume (3M)N/A

Market Cap

$150.00

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta130.29

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding1,499,000

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.00

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

PARD FAQ

What was Poniard Pharmaceuticals’s price range in the past 12 months?

Poniard Pharmaceuticals lowest stock price was $0.31 and its highest was $0.31 in the past 12 months.

What is Poniard Pharmaceuticals’s market cap?

Poniard Pharmaceuticals’s market cap is $150.00.

When is Poniard Pharmaceuticals’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Poniard Pharmaceuticals’s earnings last quarter?

Currently, no data Available

Is Poniard Pharmaceuticals overvalued?

According to Wall Street analysts Poniard Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Poniard Pharmaceuticals pay dividends?

Poniard Pharmaceuticals does not currently pay dividends.

What is Poniard Pharmaceuticals’s EPS estimate?

Poniard Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Poniard Pharmaceuticals have?

Poniard Pharmaceuticals has 1,499,000 shares outstanding.

What happened to Poniard Pharmaceuticals’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Poniard Pharmaceuticals?

Currently, no hedge funds are holding shares in PARD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers. The company has advanced Picoplatin through several clinical stages, including a pivotal Phase III SPEAR trial for small cell lung cancer patients in a second-line treatment setting. Furthermore, Phase II studies investigated Picoplatin as an initial therapy for metastatic colorectal cancer and hormone-refractory prostate cancer. An early-stage Phase I trial also examined an oral formulation of Picoplatin for solid tumors. Founded in 1984 as NeoRx Corporation, the company rebranded to Poniard Pharmaceuticals, Inc. in September 2006 and operates from its base in Seattle, Washington.